Objective To validate midregional proatrial natriuretic peptide (MR-proANP) for outcome prediction and diagnosis of cardioembolic stroke etiology compared to established clinical variables.
Blood markers measured immediately after an acute ischemic stroke may represent important adjuncts to traditional risk factors in the emergency setting. Tailoring treatment based on reliably estimated risk may improve patient outcome.
In routine clinical practice, blood biomarkers can be useful if they improve the prognostic accuracy of established clinical variables such as age and stroke severity. 1, 2 However, before biomarkers are implemented in clinical practice, validation is crucial, as shown by a meta-analysis suggesting that pilot studies on blood biomarkers typically report higher effect sizes than subsequent larger validation studies of the same blood marker. 3 Previous monocentric studies have shown that midregional proatrial natriuretic peptide (MR-proANP) is a promising prognostic and diagnostic biomarker among patients with acute ischemic stroke. In particular, MR-proANP improved the discriminatory ability of the NIH Stroke Scale (NIHSS) score 4 for 90-day mortality. 5 Through an independent, multicenter prospective cohort study, we aimed to validate the accuracy of MR-proANP in predicting functional outcome and mortality compared to established clinical variables. Moreover, this study sought to evaluate the accuracy of MRproANP for identifying cardioembolic stroke and atrial fibrillation.
Methods
Standard protocol approvals, registrations, and patient consents This study (Copeptin for Risk Stratification in Acute Stroke Patients [CoRisk] study; clinicaltrials.gov, NCT00878813) was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the local ethics committees. All patients or their welfare guardians provided written informed consent for the collection of data, blood samples, and subsequent analyses.
Study design and cohort description
The methodology of this multicenter cohort study has been published previously. 6 Briefly, the primary endpoint included disability (modified Rankin Scale [mRS] score [3] [4] [5] and mortality (mRS score 6) at 90 days after stroke. We included patients >18 years of age with an acute ischemic stroke within 24 hours of symptom onset admitted consecutively to the emergency department of each tertiary care center between March 24, 2009 , and April 8, 2011 . None of the patients enrolled in this study were part of a previous cohort evaluating MR-proANP. 5 We defined acute ischemic stroke according to the World Health Organization criteria as an acute focal neurologic deficit lasting >24 hours with no sign of acute intracranial bleeding on cerebral imaging. 7 Neither MRI nor a lesion on diffusionweighted imaging (DWI) was mandatory for the diagnosis of stroke.
Exclusion criteria were missing informed consent; TIAs (duration ≤24 hours) regardless of DWI lesions, as prespecified in the published protocol 8 ; and any other diagnosis different from ischemic stroke. Vascular neurologists prospectively recorded the NIHSS score on admission. CT or MRI was performed in each patient. MR-DWI was available for 537 stroke patients (68.5%). DWI lesion volumes were measured by experienced raters unaware of the clinical and laboratory findings. The lesion size was calculated by a commonly used semiquantitative method as previously described. 9 Lesions were categorized into 3 size classes: small lesion with a volume of <10 cm 3 , medium lesion with a volume of 10 to 100 cm 3 , or large lesion with a volume >100 cm 3 . 10 Demographic and vascular risk factors were collected on admission. Moreover, comorbidities were assessed on admission by the modified Charlson Comorbidity Index. 11 Data on cardiac and neurovascular ultrasound and 24-hour ECGs were gathered to define stroke etiology according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. 12 Biomarker measurement Blood was drawn in the emergency room within 24 hours of symptom onset. Samples were immediately centrifuged, divided into aliquots, and frozen at −80°C until the time of analysis. MR-proANP levels were assessed in plasma in a blinded batch analysis with the automated B·R·A·H·M·S KRYPTOR immunoassay technology (BRAHMS GmbH, Hennigsdorf, Germany). The lower detection limit was 2.1 pmol/L, and the functional assay sensitivity was <10 pmol/L (<20% interassay coefficient of variation, defined as the ratio of the SD to the mean). Median MR-proANP levels in healthy controls were reported to be 46.1 pmol/L and the 97.5 percentile was at 85.2 pmol/L. 13 Glossary AUC = area under the ROC curve; BNP = brain natriuretic peptide; CI = confidence interval; CoRisk = Copeptin for Risk Stratification in Acute Stroke Patients; DWI = diffusion-weighted imaging; eGFR = estimated glomerular filtration rate; IQR = interquartile range; MR-proANP = midregional proatrial natriuretic peptide; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; NRI = net reclassification index; NT-proBNP = N-terminal probrain natriuretic peptide; OR = odds ratio; ROC = receiver operating characteristic; TOAST = Trial of Org 10172 in Acute Stroke Treatment.
Follow-up and outcome measures Three months after stroke, vascular neurologists and trained study nurses blinded to MR-proANP levels assessed outcome either during an outpatient visit or with a structured telephone interview. Unfavorable outcome was defined as an mRS score of 3 to 6 points. If patients died within the follow-up period, the date of death was recorded. Cardioembolic stroke was defined according to the TOAST classification. Furthermore, atrial fibrillation, as outcome variable, was defined as diagnosis of atrial fibrillation at hospital discharge, thus encompassing history of atrial fibrillation on admission and newly diagnosed atrial fibrillation during hospitalization.
Statistical analysis
Discrete variables were expressed as counts (percentages) and continuous variables as medians (interquartile range [IQR] ). Biomarker data were log-transformed to achieve normality. The Shapiro-Wilk test was used to test for normality. Frequency comparisons for categorical baseline measurements were performed by the Fisher exact test. Two-group comparison of continuous, not normally distributed baseline data was performed by the Mann-Whitney U test. We used the Bonferroni method to correct p values for multiple univariate comparisons; i.e., we multiplied the uncorrected p values by the number of comparisons. To investigate the association of MR-proANP with functional outcome, cardioembolic etiology, and atrial fibrillation, we calculated logistic regression models, and for the association with mortality, we computed Cox regression models. To illustrate the mortality rate, patients were stratified by quartiles of MR-proANP levels, and Kaplan-Meier curves were computed and compared with the log-rank test. Odds ratios (ORs), hazard ratios, and 95% confidence intervals (CIs) were calculated, unadjusted and adjusted for demographic and vascular risk factors. As covariates for the multivariate models, we selected all the variables with a univariate p <0.01 and, regardless of the p value, thrombolysis, heart failure, and cardioembolic stroke for the models concerning functional outcome and mortality. For cardioembolic stroke and atrial fibrillation as outcome, all the variables with a univariate p <0.01 were included. Coronary heart disease was not included in any model because of collinearity with atrial fibrillation.
Interaction analyses were performed to investigate whether the predictive value of MR-proANP is modified by sex, age, stroke severity (NIHSS scores 0-6, 7-15, and >15), hypertension, diabetes mellitus, atrial fibrillation, heart failure, and estimated glomerular filtration rate (eGFR), categorized to represent relevant renal disease (cutoff <60 mL/min/ 1.73 m 2 ). The calibration of the logistic and Cox models was assessed with the Hosmer-Lemeshow goodness-of-fit test and Groennesby and Borgan test, respectively.
Receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) as an overall discriminatory measure were calculated. The De Long test was used to compare the AUCs of 2 different single variables, whereas the likelihood ratio test was used to compare the AUCs of nested vs whole models. The whole model included all predictors that remained significant in the multivariate model (p <0.05). In addition, we calculated cutoff ranges of MR-proANP (from 95% sensitivity to 95% specificity) for the main outcome measures (i.e., functional outcome, mortality, cardioembolic stroke, and atrial fibrillation).
To further estimate the additive benefit of MR-proANP levels to the traditional outcome predictor, we calculated the net reclassification index (NRI) on the basis of the model including predictors that remained significant in the multivariate model (p <0.05). The NRI has been proposed to evaluate prognostic biomarkers. 2, 14 pmol/L, p < 0.001) (table 1 and figure e-1, http://links.lww. com/WNL/A110). In the multivariate logistic regression model, MR-proANP levels were associated with an unfavorable outcome (adjusted OR 2.46 for any 10-fold increase of MRproANP, 95% CI 1.05-5.74, p = 0.038). Additional predictors of unfavorable outcome were age, stroke severity, eGFR, and large lesion size on DWI, and after adjustment for cardioembolic stroke and heart failure, MR-proANP remained associated with functional outcome (table 2) . The multivariate models were well calibrated according to the goodness-of-fit test (HosmerLemeshow p = 0.4). No significant interactions were found across subgroups for the prediction of functional outcome.
MR-proANP improved only marginally the discriminatory accuracy of the NIHSS and the whole multiple logistic regression model ( pmol/L, p < 0.001) (figure e-3, http://links.lww.com/WNL/ A110). The Kaplan-Meier survival curves of patients stratified per MR-proANP quartiles differed significantly (p < 0.001, log-rank test, figure e-4).
In the multivariate Cox regression model, MR-proANP was associated with 90-day mortality with a hazard ratio of 6.12 (95% CI 2.36-15.84, p = 0.01). Table 2 summarizes additional predictors of mortality, including heart failure and cardioembolic stroke etiology. The multivariate models were well calibrated Abbreviations: CI = confidence interval; DWI = diffusion-weighted imaging; eGFR = estimated glomerular filtration rate; IA = intra-arterial; MR = magnetic resonance; MR-proANP = midregional proatrial natriuretic peptide; NA = not applicable; NIHSS = NIH Stroke Scale; OR = odds ratio. a ORs and hazard ratio refer to a 1-unit increase in the explanatory variable and to any 10-fold increase in MR-proANP, glucose, C-reactive protein, and eGFR (log transformed with a base of 10). All of the covariates entered in the models are listed in the table. pmol/L had a sensitivity of 81% and a specificity of 56% for death within 3 months (table e-2, http://links.lww.com/WNL/A111).
The combination of MR-proANP with the Cox regression model led to a continuous NRI of 49% (95% CI 26%-78%, p < 0.001) and categorical NRI of 16% (95% CI 9.5%-29.0%, p < 0.001).
Identification of cardioembolic stroke and atrial fibrillation
Median MR-proANP levels were almost twice as high in patients with cardioembolic stroke compared to other stroke pmol/L had a specificity of 86% and a sensitivity of 48% for the diagnosis of atrial fibrillation at hospital discharge (table e-2) . Adding MR-proANP to significant predictors of atrial fibrillation increased the AUC from 0.70 (95% CI 0.67-0.74) to 0.79 (95% CI 0.76-0.82, p < 0.001) (table e-6), leading to a continuous NRI of 78% (95% CI 60%-89%, p < 0.001) and a categorical NRI of 39% (95% CI 27%-55%, p < 0.001).
Discussion
In this prospective multicenter cohort of acute ischemic stroke patients, MR-proANP was an independent predictor of functional outcome, mortality, cardioembolic stroke etiology, and atrial fibrillation. Of note, across the analyzed subgroups, the association between MR-proANP and the outcome variables remained significant. When MR-proANP was added to prognostic models using different statistical methods (i.e., comparison of AUCs, NRI, and change in pseudo-R 2 ), we found an improvement for mortality and the identification of atrial fibrillation. Our multicenter study confirms and extends the conclusions of a previous single-center cohort study of 362 patients with acute ischemic stroke, which also found an independent association between MR-proANP and mortality, as well as cardioembolic stroke. 5 Because of the larger sample size of the current study, it was possible to adjust for several prognostic factors, to compare subgroups, and to assess the incremental value of MR-proANP beyond the most important demographic and vascular risk factors.
In stroke research, brain natriuretic peptide (BNP) has been shown to predict all-cause mortality and, in some studies, functional outcome. 5, 15 In a meta-analysis of 3,498 patients with ischemic stroke, BNP and N-terminal probrain natriuretic peptide (NT-proBNP) added information to clinical predictors (NIHSS score, age, sex) for the prediction of mortality (NRI 8.1%) but not for functional outcome, 16 which is in line with our observation that MR-proANP had a better prognostic accuracy for mortality rather than functional outcome. The pathophysiologic relationship between elevated levels of natriuretic peptides and stroke prognosis is still unclear. The highest ANP levels within the CNS are found in the hypothalamus and septum. 17 Activation of the hypothalamuspituitary-adrenal axis is associated with elevated levels of natriuretic peptides. High cortisol, copeptin, and natriuretic peptide values predict long-term mortality after ischemic stroke, suggesting that a neurohumoral disturbance is linked to unfavorable outcome. 5, 18 In addition, ANP is secreted by Abbreviations: CI = confidence interval; MR-proANP = midregional proatrial natriuretic peptide; NA = not applicable; OR = odds ratio. a OR refers to a 1-unit increase in the explanatory variable and to any 10-fold increase in MR-proANP (log transformed with a base of 10). All of the covariates entered in the model are listed in the table.
atrial myocytes in response to different stimuli such as atrial distension, angiotensin II stimulation, endothelin, and sympathetic stimulation. 19, 20 The prohormone of ANP, known as MR-proANP, has a longer half-life and makes serum measurements more feasible. 21 For the diagnosis of acute heart failure, MR-proANP has been shown to be noninferior to BNP and seemed to improve the diagnostic accuracy of BNP levels between 100 and 500 pg/ mL. 22 In chronic heart failure, with regard to mortality, MR-proANP outperformed BNP and NT-proBNP. The proportion of explained variance (4.36%) showed that MRproANP was a significantly stronger predictor of death than either NT-proBNP (2.47%, p < 0.0001) or BNP (2.42%, p < 0.0001). Both the high biological stability of MR-proANP and a new assay technology are potential explanations for these findings.
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The independent association of natriuretic peptides with cardioembolic stroke (after adjustment for age and evident atrial fibrillation) could be explained through an underlying atrial cardiopathy, which can presumably anticipate even atrial fibrillation. 24 Thus, ANP may be a potential blood marker of atrial cardiopathy, which is also associated with cardioembolic stroke. 24 There may even be a causal relationship of ANP with the development of atrial fibrillation because individuals with familial atrial fibrillation demonstrate a frameshift mutation in the gene encoding ANP. 25 Because up to 30% of patients with cryptogenic stroke may have undetected paroxysmal atrial fibrillation or other unrecognized cardioembolic sources, 26 MR-proANP levels might help identify patients who will benefit from prolonged cardiac rhythm monitoring or oral anticoagulants for recurrence prophylaxis. However, among patients with strokes initially considered cryptogenic, additional studies are needed to assess the association of MR-proANP with paroxysmal atrial fibrillation and cardioembolism.
This study has limitations. First, the study is lacking a direct comparison of MR-proANP with other natriuretic peptides. Second, the proportion of patients with cardioembolic stroke was somewhat higher compared to other epidemiologic studies. Possible explanations include referral bias, because patients with cardioembolic stroke tend to have more severe strokes and be referred to tertiary care centers like the ones participating in this study, and a higher detection rate of cardioembolic sources due to extensive cardiac workup (almost half of the patients underwent transesophageal echocardiography). Third, no follow-up data on the detection of atrial fibrillation after hospitalization were available, leaving the question of whether MR-proANP would help reclassify cryptogenic into cardioembolic stroke. Fourth, some baseline variables were missing, including the proportion of patients with anterior vs posterior circulation and the frequency of large vessel occlusion, which may contribute to outcome prediction. Fifth, MR-proANP was associated not only with mortality but also with other factors such as age, NIHSS score, infarct size, hypertension, and diabetes mellitus, which were adjusted for with a Cox regression model. However, residual confounding effects cannot be excluded. Finally, the interrater agreement of the 2 raters of DWI lesion volumes was not available.
In the emergency setting, MR-proANP can improve the risk stratification for 90-day mortality after stroke. Higher MRproANP levels were also associated with cardioembolic stroke etiology and, even more strongly, atrial fibrillation. In the future, MR-proANP may facilitate the selection of patients who will benefit from prolonged cardiac rhythm monitoring and anticoagulation. 
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Study question
Can midregional proatrial natriuretic peptide (MR-proANP) levels within the first 24 hours of ischemic stroke onset improve the prediction of 90-day mortality, functional outcomes, and cardioembolic stroke etiology?
Summary answer
The MR-proANP level was an independent predictor of functional outcome, mortality, cardioembolic stroke etiology, and atrial fibrillation; however, the inclusion of MR-proANP levels improved prognostic models for mortality and atrial fibrillation only.
What is known and what this article adds
Previous single-center studies have reported that inclusion of MR-proANP levels improves the discriminatory ability of the NIH Stroke Scale (NIHSS) score for 90-day mortality. In this multicenter study, we verified the prognostic utility of MR-proANP levels regarding several outcome measures.
Participants and setting
This prospective, multicenter cohort study included 788 consecutive patients (median age 71 years; 62% men) admitted to the emergency departments of participating tertiary centers within 24 hours of acute ischemic stroke onset.
Design, size, and duration Outcomes of interest included 90-day mortality, unfavorable outcomes (modified Rankin Scale score >2 points), diagnoses of cardioembolic stroke etiology during hospitalization, and atrial fibrillation. Blood samples for the assessment of MR-proANP levels were obtained within 24 hours of symptom onset. Regression models and the net reclassification index (NRI) were used to estimate the additive benefit of MR-proANP levels to traditional outcome predictors.
Main results and the role of chance Inclusion of MR-proANP levels increased the discriminatory accuracy of mortality and atrial fibrillation prediction, but not of functional outcome and cardioembolic etiology. The NRI of MR-proANP for mortality was 49% (95% confidence interval [CI] 26%-78%, p < 0.001), and for atrial fibrillation 78% (95% CI 60%-89%, p < 0.001). While MR-proANP levels ≥163 pmol/L had a specificity of 56% and a sensitivity of 81% for 90-day mortality, levels ≥289 pmol/L had a specificity of 86% and sensitivity of 48% for atrial fibrillation.
Bias, confounding, and other reasons for caution MR-proANP levels were not compared with levels of other natriuretic peptides. Residual confounding effects of associations between MR-proANP levels and other factors cannot be excluded.
Generalizability to other populations
Because of the study's multicenter design, and broad inclusion criteria, the results may be generalizable to various populations of patients with stroke. Abbreviations: DWI = diffusion weighted imaging; eGFR = estimated glomerular filtration rate; MR = magnetic resonance; MR-proANP = midregional proatrial natriuretic peptide; NA = not applicable; NIHSS = NIH Stroke Scale. a Odds ratio refers to a 1-unit increase in the explanatory variable and to any 10-fold increase in MR-proANP and eGFR (log-transformed with a base of 10). All of the covariates entered in the models are listed in the table.
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